New Name Better Reflects Breadth of Products and Long-Term Vision for Growth
FORT WORTH, TX / ACCESSWIRE / April 3, 2018 / Wound Management Technologies Inc. announced today that it is changing its name to WNDM Medical Inc. to better align with the company's innovative and cost-effective products across the surgical continuum of care.
"Over the years, we've expanded beyond wound care," says J. Michael Carmena, CEO of WNDM. "It made sense to have a company name that reflected our breadth of products."
As part of the rebrand, WNDM also unveiled a new corporate logo and changed its website address to WNDM.com.
"We pride ourselves on developing new products that have a positive impact on clinical outcomes," Carmena said. "While we'll stay focused on growing our product offerings, the high level of quality and effectiveness our customers have come to expect will remain the same."
Based in Fort Worth, Texas, WNDM Medical has a solid new management team in place that is committed to growing the company while also bolstering the brand's equity. By merging science and technology, WNDM Medical develops products that are on the leading edge of the surgical industry for physicians, hospitals, and clinics across the U.S.
About WNDM Medical Inc.
With its No. 1 goal of improving patient outcomes, WNDM Medical Inc. (OTCQB: WNDM) develops, markets and distributes biotechnology products to physicians, hospitals, and clinics. It has a strong history of developing long-term strategic partnerships with a focus on products that fuse nature and science with medicine. Its primary products are in the $11 billion U.S. consumable medical device market and the $1.5 billion biomaterials market. WNDM Medical sells and distributes CellerateRX®/CRXα® Surgical Activated Collagen® Adjuvant and HemaQuell® Resorbable Bone Hemostat. For more information, visit WNDM.com.
Information about Forward-Looking Statements
The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance, and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the Company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by, these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
SOURCE: Wound Management Technologies Inc.